An 83-year-old high-risk gentleman diagnosed with severe symptomatic aortic stenosis was scheduled for TAVR. A 31 mm CoreValve was implanted but severe paravalvular leak was noted. A valve-in-valve procedure was performed. However, the valve frame was partially dislodged into de ascending aorta. We report our strategy to solve this severe leak after a failed valve-in-valve procedure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497244 | PMC |
| http://dx.doi.org/10.1016/j.ijcha.2015.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioprosthetic Aortic Valve Degeneration After TAVR and SAVR: Incidence, Diagnosis, Predictors, and Management.
J Cardiovasc Dev Dis
November 2024
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Bioprosthetic aortic valve degeneration (BAVD) is a significant clinical concern following both transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). The increasing use of bioprosthetic valves in aortic valve replacement in younger patients and the subsequent rise in cases of BAVD are acknowledged in this review which aims to provide a comprehensive overview of the incidence, diagnosis, predictors, and management of BAVD. Based on a thorough review of the existing literature, this article provides an updated overview of the biological mechanisms underlying valve degeneration, including calcification, structural deterioration, and inflammatory processes and addresses the various risk factors contributing to BAVD, such as patient demographics, comorbidities, and procedural variables.
View Article and Find Full Text PDFBalloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction with en face view for patients exhibiting severe calcified leaflet: a case report.
Eur Heart J Case Rep
December 2024
Department of Cardiology, Sendai Kousei Hospital, 1-20, Tsutsumidori Amamiya-cho, Aoba-ku, Sendai, Miyagi 981-0914, Japan.
Background: Balloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BA-BASILICA) enables valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) in patients at risk of coronary artery obstruction. However, its efficacy in patients with severely calcified leaflets remains unclear.
Case Summary: We report a 78-year-old woman with a deteriorated 21 mm Carpentier-Edwards PERIMOUNT Magna valve.
Surgical or Transcatheter Mitral Valve Replacement After Prior Bioprosthesis or Ring Implantation: A Landmark Analysis of Early and Long-Term Outcomes.
J Clin Med
November 2024
Department of Cardiac Surgery, Klinikum Nürnberg-Paracelsus Medical University, Breslauer Strasse 201, 90471 Nuremberg, Germany.
In recent years, the use of transcatheter valve-in-valve implantation in the mitral position (TMVI) for the treatment of mitral valve pathology following ring or bioprosthetic implantation has emerged as a less invasive option in comparison to repeated mitral valve surgery (RMVS). We aimed to compare the early and mid-term results of these two strategies. We retrospectively analyzed all patients who underwent a mitral intervention in our institution between 2005 and 2022.
View Article and Find Full Text PDFYearly Trends and In-Hospital Outcomes of Patients Undergoing Transcatheter Mitral Valve-In-Valve Replacement in Prosthetic Valve Dysfunction.
Catheter Cardiovasc Interv
December 2024
Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA.
Introduction: Transcatheter mitral valve-in-valve replacement (TMVR ViV) is becoming a favorable, less invasive procedure among high-risk patients to manage mitral valve dysfunction. We aimed to investigate the trends of the predictors and outcomes of the procedure.
Methods: The national inpatient sample databases of 2016-2020 were analyzed using STATA 17 software and ICD-10 codes for TMVR ViV, with stratification for mitral stenosis (MS) or Mitral regurgitation (MR) as etiology for prosthetic valve dysfunction.
Same-Day Discharge After Uncomplicated Transcatheter Tricuspid Valve-In-Valve Implantation.
Catheter Cardiovasc Interv
December 2024
Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA.
Background: Tricuspid valve-in-valve (TVIV) implantation has traditionally included post-procedure overnight in-hospital observation with next-day discharge. Recently, our practice has shifted toward same-day discharge for most patients after vascular access site hemostasis and adequate recovery from anesthesia. However, data on the safety of this approach remains scarce.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!